London, 11 February 2020 - This significant milestone sees a best in class, novel multi-target drug developed using BenevolentAI's scientific and technical expertise now entering human clinical trials.
BEN-2293 is a potent and selective small-molecule Pan-Trk antagonist formulated for topical delivery, with a pharmacokinetic profile designed for low systemic exposure to deliver the optimal safety and efficacy profile in the treatment of itch and inflammation associated with Atopic Dermatitis. In this initial trial, BEN-2293 will be studied in adult patients with mild to moderate disease.
Atopic Dermatitis is characterised as a chronic relapsing inflammatory skin condition which manifests as itchy, inflamed skin. The addressable global patient population is estimated at 230 million. Mild to moderate Atopic Dermatitis affects approximately 70% of all patients, with prevalence rising worldwide.
The current standard of care for the topical treatment of Atopic Dermatitis includes corticosteroids and calcineurin inhibitors which have limitations of use and adverse side effects. There remains a high unmet need for patients that are either non-responders or refractory to currently available treatments. BEN-2293 is positioned to address both the inflammation and itch associated with Atopic Dermatitis in both adults and children, representing a comprehensive, new treatment available for a broad patient population.
“The poor treatment options available for Atopic Dermatitis patients make the disease difficult to endure. It can impact the quality of life and psychosocial wellbeing, particularly among children, who make up around 10-20% of patients. New ways to treat this disease are desperately needed, and we believe our molecule has strong potential to address this serious unmet need without the use of topical steroids. The BEN-2293 trial also marks an important first step in the development of our in-house drug pipeline, and we are excited to be progressing this candidate into the clinic.”
BenevolentAI creates and applies AI and machine learning to transform the way medicines are discovered and developed. Benevolent integrates its technology into every step of the drug discovery process, from hypothesis generation to early-stage clinical development. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and offices in New York. BenevolentAI has active R&D drug programmes in disease areas such as ALS, Ulcerative Colitis, Atopic Dermatitis and Oncology and has research and commercial collaborations with AstraZeneca and Novartis.